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This study analyzes the results of clinical trials of treatments with melatonin conducted in children, mostly focused on sleep
disorders of diﬀerent origin. Melatonin is beneﬁcial not only in the treatment of dyssomnias, especially delayed sleep phase
syndrome, but also on sleep disorders present in children with attention-deﬁcit hyperactivity, autism spectrum disorders, and, in
general, in all sleep disturbances associated with mental, neurologic, or other medical disorders. Sedative properties of melatonin
have been used in diagnostic situations requiring sedation or as a premedicant in children undergoing anesthetic procedures.
Epilepsy and febrile seizures are also susceptible to treatment with melatonin, alone or associated with conventional antiepileptic
drugs. Melatonin has been also used to prevent the progression in some cases of adolescent idiopathic scoliosis.In newborns, and
particularlythosedeliveredpreterm, melatoninhasbeenusedtoreduce oxidativestressassociatedwithsepsis,asphyxia,respiratory
distress, or surgical stress. Finally, the administration of melatonin, melatonin analogues, or melatonin precursors to the infants
through thebreast-feeding, orby milkformulaadapted fordayandnight,improves theirnocturnal sleep. Sideeﬀects ofmelatonin
treatments in children have not been reported. Although the above-described results are promising, speciﬁc studies to resolve the
problem of dosage, formulations,and length of treatment are necessary.
1.Introduction
Since the identiﬁcation and isolation of melatonin from
bovine pineals [1], especially in the last 20 years, numerous
clinical trials were designed to study the possible therapeutic
usefulness of this pineal indoleamine in diﬀerent ﬁelds of
medicine [2]. The objective of this paper is to review, in
depth, the state of the art on the clinical uses of melatonin in
pediatrics. Although, at present, many experimental studies
are providing the basis for future clinical applications of
melatonin in diﬀerent pediatric pathologies (i.e., obesity,
enuresis, etc.), this paper focuses only on those medical
applications which have been already assessed in clinical
trials. Some of the basic aspects on the usefulness of
melatonin in this clinical area have been recently reviewed
by Gitto et al. [3]; the readers are also referred to this paper.
Among the wide spectrum of properties attributed to
melatonin, perhaps one of the most solidly based is its
regulation of the sleep/wake cycle [4]. Thus, it is not
surprising that most clinical applications of melatonin in
pediatrics are focused on childhood sleep disorders of
diﬀerent origin but especially of circadian etiology. Also,
when melatonin was used for this purpose in children, it is
noteworthy that signiﬁcant side eﬀects of the indoleamine
have not been reported [5].
2.MelatoninUsesforChildren’sSleepDisorders
Among elementary school children, bedtime resistance is
the most prevalent sleep problem (27%). Sleep-onset delays
(11.3%), night waking (6.5%), morning wakeup problems
(17%), and fatigue complaints (17%) are also common
[6]. Although sleep problems of diﬀerent etiology are the
frequent cause of medical consults, there are no speciﬁc
prescription drugs for the treatment of insomnia in children,
and many pediatricians recommended behavioural treat-
ments in an attempt to correct sleep problems in infants.
However, melatonin is being prescribed as a medication
associated to behavioural treatment for sleep disorders by2 International Journal of Pediatrics
an increasing number of physicians, judging from a survey
carried out by Owens et al. [7].
The hypothesis of the relationship between melatonin
and sleep was founded on the coincidence of highest
circulating levels of melatonin and depressed core body
temperature [8] with the greatest nocturnal sleepiness [9].
Furthermore, in some individuals, the administration of
physiologic doses (0.1–0.3mg) of melatonin promotes sleep
onset and maintenance, decreases sleep latency, increases
sleep eﬃciency, and improves total sleep time [10, 11]. A
review of the basic mechanism involved in melatonin’s sleep
regulationcanbefoundinapublicationbyDubocovich[12].
The American Academy of Sleep Medicine, in The
International Classiﬁcation of Sleep Disorders (ICSD) [13],
deﬁnes four categories: (1) dyssomnias, (2) parasomnias, (3)
sleep disorders associated with mental, neurologic, or other
mental disorders, and (4) proposed sleep disorders. In this
paper, we consider the possible usefulness of melatonin in
children in some sleep disorders included in groups 1 and 3
of this classiﬁcation.
2.1.Dyssomnias. TheICSDdeﬁnesdyssomnias as“thedisor-
ders that produce either diﬃculty initiating or maintaining
sleep.” This section includes the circadian rhythm sleep
disorders (those related to the timing of sleep during the 24-
hour day) and, among them, delayed sleep-phase syndrome
(DSPS) and advanced sleep-phase syndrome (ASPS). The
DSPS is a disorder in which the major sleep episode is
delayed in relation to the desired clock time, resulting in
symptoms of sleep onset or diﬃculty in awakening at the
desired time [13]. Typically, patients with DSPS fall asleep
severalhours after midnight and have diﬃcultywaking up in
the morning [14]. In the ASPS, the problemis that the major
sleep episode is advanced in relation to the desired clock
time, and the patients exhibit an early sleep onset (evening
sleepiness) and an early awakening. While ASPS is very rare
among children but frequently encountered in the elderly
and in postmenopausal women, DSPS usually develops in
early childhood or adolescence, and it is more prevalent
amongyoungerpeople[14].Thetime ofmelatonin secretion
onsetinDSPSpatientsissigniﬁcantlydelayedcomparedwith
healthy controls [15].
S e v e r a lc l i n i c a lt r i a l sh a v ee v a l u a t e dt h ee ﬃcacy of
melatonin as a therapy for DSPS in adults [16]. In children,
only a retrospective study [17] describes the eﬀects of long-
term treatment with melatonin (3–5mg/day for an average
period of 6 months) in 33 adolescents with DSPS. This
treatment advanced the sleep onset and increased sleep
duration and was also associated with a reduction in the
proportion of patients reporting school diﬃculties [17].
There also is a relationship between timing of melatonin
administration and phase changes in patients with DSPS.
Thus, in a double-blind placebo-controlled trial carried out
on 13 subjects with DSPS, melatonin (0.3 or 3.0mg) or
placebo was administered for a 4-week period, between 1.5
and 6.5 hours prior to DLMO (dim light melatonin onset).
DLMO, the time of the evening melatonin rise under dim
light environment [18], is an excellent marker of circadian
phase of endogenous melatonin which can be measured in
the awake patient, before sleep time; the DLMO provides
valuable information about thep h a s eo ft h ec i r c a d i a np a c e -
maker [15, 19]. The magnitude of phase advance in DLMO
and the advance in sleep time were higher at earlier times
of melatonin administration [20]. Recently, a randomized,
placebo-controlled double-blind trial carried out on 72
children with chronic sleep onset insomnia, treated during
a week with either melatonin (0.05, 0.1, or 0.15mg/kg) or
placebo, reported even with the lowest doses a signiﬁcant
(1h) advance of the sleep onset and DLMO as well as a
shortening of sleep latency [21]. These eﬀects of melatonin
are greatest when treatment is administered at least 1-2h
before DLMO [21]. In a review on circadian rhythm sleep
disorders, sponsored by the American Academy of Sleep,
Sack et al. [22] concluded that “The evidence is quite strong
thatmelatonin,timedtopromoteacorrectivephaseadvance,
is an eﬀective treatment for DSPS”; this suggests additional
studies to determine the optimal parameters for dosing and
scheduling. For practical reasons, since determination of
DLMO is not a usual clinical procedure, it is good practice to
administer melatonin just before the desired bedtime. When
melatonin is given 30 minutes before bedtime, the hypnotic,
more than the chronobiotic, eﬀectsof the indoleamine could
potentially ameliorate the sleep-onset diﬃculties in patients
with DSPS [20, 21].
2.2. Sleep Disturbances Associated with Mental, Neurologic,
or Other Medical Disorders. Irregular patterns of sleep-wake
rhythm are commonly associated with neurological impair-
ment [23], and the possible therapeutic value of melatonin
for these sleep disorders has been assessed in several clinical
trials [24]. The neurological diseases that are associated with
sleep disorders included mental or intellectual disability,
mental retardation, learning disabilities, autistic spectrum
disorders, Rett syndrome, tuberous sclerosis, developmental
disabilities, and Angelman syndrome. A recent meta-analysis
[25] of data from 9 randomised placebo-controlled trials
published between 1990 and 2008 comprising a sample of
183 patients concluded that melatonin, at doses ranging
from 0.5 to 9mg, decreases sleep latency, increases total
sleep time, and reduces the number of awakenings per night
in individuals with intellectual disabilities. Other clinical
trials not included in the above-mentioned meta-analysis
showed similar results. Thus, Jan et al., [26] in a pioneering
study in this ﬁeld, noted that in 15 children with diﬀer-
ent neurological problems associated with severe chronic
sleep disorders unresponsive to conventional management,
when given 2 to 10mg of oral melatonin, a signiﬁcant
improvement of their sleep and behavioral problems was
apparent. Similarly, Zhdanova et al. [27]r e p o r t e dt h a t
0.3mgmelatoninimprovedtheobjectiveandsubjectivesleep
quality of children with Angelman syndrome, while Pillar et
al. [28], in ﬁve children (mean age 8.2 ± 3.6y e a r s )w i t h
severe psychomotor retardation and with irregular sleep-
wakepatterns,reported thatmelatonintreatment(3mg/day)
increased signiﬁcantly nighttime sleep and sleep eﬃciency
and reduced daytime sleep [28].
Not only blind children with other neurologic patholo-
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have associated sleep-wake cycle disorders [29]. Several case
reports [30–32]a sw e l la sa no p e ns t u d yi n8c h i l d r e na n d
young adults [33] recommended the treatment of these sleep
disorders with melatonin. Most totally blind children, in
the absence of an entraining light-dark cycle, develop free
running sleep/wake rhythms [34, 35]. These children may
beneﬁt from therapy with melatonin.
Among the mental and neurological disorders with
associated sleep problems, several pathologies have been
especially considered for treatment with melatonin and
deserve particular emphasis. This includes autism spectrum
disordersandattention-deﬁcithyperactivitydisorder.Smith-
Magenis and Sanﬁlippo syndromes, pathologies also associ-
ated with sleep disturbances susceptible of treatment with
melatonin, will be also analyzed in depth.
2.3. Autism Spectrum Disorders (ASDs). Insomnia is the pre-
dominant sleep concern in children with ASD,and its nature
is most likely multifactorial including several neurochemical
etiologies (e.g., abnormalities in serotonergic transmission
or melatonin levels). The etiologic role of melatonin in
sleep problems associated with ASD has been suggested in
numerous studies [36, 37]. Children with ASD show lower
melatonin levels than healthy children [38], possibly caused
by a primary deﬁcit in one or both of the enzymes, that
is, AA-NAT (aralkylamine N-acetyltransferase) and ASMT
(acetylserotonin methyltransferase, also known as HIOMT:
hydroxyindole O-methyltransferase), which are responsible
for the conversion of N-acetylserotonin to melatonin. The
gene coding for ASMT enzyme is frequently mutated in
ASD pat [39, 40]. Possible mutations in genes coding for
melatonin receptors in patients with ASD also have been
studied although without conclusive results [41].
Melatonin has been assessed for its possible usefulness
in the treatment of sleep troubles of ASD patients for more
than 15 years (see the most recent reviews, [42, 43]). In a
study of 15 children (6–17 years) with Asperger disorder,
a form of ASD, treated with melatonin (3mg) for 14
days, sleep and behavioral improvements were observed
in response to melatonin [44]. These were conﬁrmed in
a randomized, placebo-controlled double-blind crossover
trial recruiting 11 children with ASD [45]. These children
received either melatonin (5mg) or placebo for a period of
4-weeks; this was followed by a washout period of 1 week
followed by a second 4-week treatment period. Although
only 7 children completed the trial, and this small sample
diminished the signiﬁcance ofthe results, the conclusionwas
that all the outcome parameters (sleep latency, awakenings
pernight,andtotalsleepduration)improvedwithmelatonin
treatment. More interesting is the study carried out by
Giannotti et al., [46]i n2 5c h i l d r e ni nw h i c ht h em e l a t o n i n
formulation (3mg) consisted of 1mg fast release and 2mg
controlled release, which was given in long term (12–24
months). Children’s Sleep Habits Questionnaire and sleep
diaries were used to assess sleep quality before and after
treatment and after discontinuation. The administration of
melatonin improved sleep parameters in all cases; 64% of
patients returned to pretreatment scores after discontinua-
tion of melatonin, but they responded again positively to the
restoration of the treatment. Controlled-release melatonin
(5mg) was also used in another randomized double-blind
placebo-controlled crossover trial in a group of 51 children
with neurodevelopmental disabilities, 16 of whom had been
diagnosed with ASD [47]. Melatonin treatment improved
the sleep of 47 of these children although the results were
globally analyzed without distinguishing the diﬀerent types
of neurodevelopmental pathologies included in the study
(cerebral palsy, epilepsy, visual impairment, etc.). An even
larger patient sample was studied by [48]. These authors
carried out a clinical trial on 107 children (2–18 years
of age) with a conﬁrmed diagnosis of ASD, treated with
melatonin (0.75–6mg). In 25% of these individuals, based
on the parent’s reports, sleep troubles disappeared; in most
cases (60%), at least a signiﬁcant improvement of sleep was
reported, although some problems persisted, 14 children
did not experience changes in their sleep quality; and,
in one patient, sleep worsened. The conclusion was that
m e l a t o n i na p p e a r st ob ea ne ﬀective, safe, and a well-
tolerated treatment for insomnia in children with ASD.
New studies have conﬁrmed these results. Thus, a 4-week,
randomized, double-blind,placebo-controlled crossoverwas
performed in which either melatonin (3mg) or placebo
was given to participants for 2 weeks; the treatments were
then crossed over for another 2 weeks. The results of this
study also support the eﬃcacy and tolerability of melatonin
treatment for sleep problems in children with ASD [49]. A
more recently published study is double-blind, randomized,
controlled crossover trial involving 22 children diagnosed
of ADS, with severe dyssomnias refractory to supportive
behavioral management. Patients were treated for 3 months
with placebo versus 3 months of melatonin (maximum
dose of 10mg). In all children (17 cases) who completed
the study, melatonin signiﬁcantly improved sleep latency
and total sleep time compared to placebo, but did not
inﬂuencethenumberofnightawakenings [50].Interestingly,
also in adults with ASD, a retrospective study reported
that melatonin (3mg at bedtime) appears to be eﬀective
in reducing sleep onset latency and is probably beneﬁcial
in improving nocturnal awakenings and total sleep time
[51].
2.4. Attention-Deﬁcit Hyperactivity Disorder (ADHD). Sleep
problems including delayed sleep onset, sleep or bedtime
resistance, prolonged tiredness upon waking, and daytime
sleepiness have been reported in 25–50% of children with
ADHD[52].Two well-controlled studieshavefocusedonthe
possible role of melatonin in the treatment of sleep disorders
in ADHD children. The ﬁrst was a double-blind, placebo-
controlled,30-daycrossovertrial carriedoutin27stimulant-
treatedchildren(6–14yearsofage)withADHD.Nonrespon-
ders to sleep hygiene guidelines were treated with melatonin
(5mg/day, 20 minutes before bedtime) or placebo. Patients
receiving melatonin experienced a signiﬁcant reduction in
sleep-onset latency compared to those treated with placebo
although the best results were obtained with the com-
bined sleep hygiene and melatonin intervention [53]. The
second study, another randomized, double-blind, placebo-
controlled trial, recruited 105 medication-free children (64 International Journal of Pediatrics
to 12 years old), with diagnosed ADHD and chronic sleep
onsetinsomnia. Participants weretreatedwithmelatonin(3–
6mg, depending on body weight), or placebo for 4 weeks.
Melatonininducedasigniﬁcantadvanceofsleeponsetaswell
as of the total time asleep as compared to placebo although
there was no signiﬁcant eﬀect on behavior, cognition, or
quality of life. Signiﬁcant adverse events did not occur [54].
T h em i n o ra d v e r s ee ﬀects with melatonin treatment did
not signiﬁcantly diﬀer from placebo in either of these two
studies. More recently, Hoebert et al. [55]e v a l u a t e dt h e
eﬀectiveness and safety of long-term (mean time up to 3.7
years) melatonin treatment in children with ADHD and
chronic sleep onset insomnia (CSOI) using questionnaires
answered by parents of patients. Interestingly, long-term
melatonin treatment was judged to be eﬀective against sleep
problemsin88%ofthecases;improvementofbehaviourand
mood was reported in 71% and 61%, respectively, whereas
no serious adverse eﬀects were reported. The last and most
complete review of the clinical studies on the eﬃcacy and
safety ofmelatonin for the treatment ofinsomnia in children
with ADHD concluded that this indoleamine is a well-
tolerated and eﬃcient therapeutic option for these pediatric
patients [56].
2.5. Smith-Magenis Syndrome (SMS) and Sanﬁlippo Syn-
drome (SFS). SMS is a multiple congenital anomaly com-
mon due to a 3.5Mb interstitial deletion of chromosome 17
band p11.2 and characterized by subtle minor craniofacial
anomalies, infantile hypotonia, skeletal ﬁndings (brachy-
dactyly, short stature, and scoliosis), developmental and
expressive language delays, mental retardation, maladaptive
and self-injurious behaviors, and sleep disturbances [57,
58]. Special consideration deserve the sleep disorders of
SMS patients which include early sleep onset, diﬃculty
falling asleep, diﬃculty staying asleep, frequent awakening,
early waking, reduced REM sleep, and decreased sleep time
[59]. These sleep problems are, in part, responsible for the
behavioural and cognitiveproblems of these children. A high
prevalence of sleep disorders, with irregular sleep episodes
of diﬀerent duration randomly distributed over the 24-hour
period, has also been described in children with SFS, a type
III mucopoysaccharidosis [60].
Whereas the rhythm of melatonin secretion in all mam-
mals, including humans, exhibits a characteristic nocturnal
increase in plasma concentration, with lower values during
the daytime, patients with SMS have a characteristic inver-
sion of the circadian rhythm of melatonin, with a phase
advance shift of 9.6 ± 0.9h with respect to control subjects
[59, 61]. SFS patients also exhibit alterations of the diurnal
rhythm of melatonin secretion, with lower concentrations
of urinary excretion of 6-sulphatoxymelatonin at night and
higher in the morning as compared with healthy controls
[62].
Since the nocturnal rise of melatonin has been related
to the induction of sleep [10], the anomalous secretory
pattern of melatonin in SMS and SFS children could, at
least in part, be responsible for their sleep disorders. On
this basis, a treatment consisting on the administration
of a β1-adrenergic antagonist in the morning (to abolish
the daytime secretion of melatonin) combined with the
administration of melatonin in the evening (to generate a
nocturnal peak, restoring the normal day/night rhythm of
melatonin), has been assessed in SMS children. The result
was a dramatic improvement in the sleep quality, evaluated
not only by actimetric and subjective methods [59, 63]
but with polysomnographic studies [64]. These children
experience a better sleep quality, reduced irritability, low
evening drowsiness, and improved learning capability. In
regard to SFS, two surveys, one among clinicians [65]a n d
another among parents of aﬀected children [66], reported
that melatonin is the medication most likely to be of beneﬁt
for sleep disorders in these patients. However, clinical trials
ofcasereportswithobjectivemeasuresofsleepqualitybefore
and after melatonin treatment have not been published.
3.Melatonin UsesinPediatricAnesthesia
The sedative, anxiolytic, anti-inﬂammatory, and hypnotic
eﬀects of melatonin [67] support the possible use of
melatonin at diﬀerent stages of anaesthetic procedures,
from premedication to induction of general anaesthesia or
postsurgical analgesia [68].
One of the proposed uses of melatonin is premedication
preceding the anesthesia induction. The use of melatonin
versus midazolam (Dormicum) as a premedicant in chil-
dren was studied in a randomized, double-blind, placebo-
controlled trial involving seven groups of 15 children who
receive one of the following premedicants: midazolam (0.1,
0.25, or 0.5mg/kg), melatonin (0.1, 0.25, or 0.5mg/kg),
or placebo. Premedication with melatonin or midazolam
was equally eﬀective in alleviating anxiety although the
use of melatonin was associated with a lower incidence of
excitement at 10min postoperatively, and a lower incidence
of sleep disturbance at week 2 postoperatively than that
observed with midazolam [69]. Other studies reported that
midazolam (0.5mg/kg) is more eﬀective than melatonin
(0.05–0.4mg/kg) in reducing children anxiety in children
although the individuals who received melatonin developed
less emergence of delirium compared to those who received
midazolam [70]. However, another comparative study of
melatonin (3mg, 0.50mg/kg BW, or 0.75mg/kg BW, 60min
before procedure) versus midazolam (15mg) or placebo was
carried out on 60 children undergoing sedation for dental
treatments. This study reported that melatonin was similar
to placebo not contributing to sedation of anxious children
[71].
Severaldiagnostic studieson children requiresedation or
general anesthesia. One example is brainstem audiometry,
an important investigative tool in pediatric audiology. In
a survey on 250 children (142 male and 108 female) who
underwent auditory brainstem response tests, melatonin-
induced sleep allowed for the completion of the exploration
in 74–87% of cases [72]. The use of melatonin, especially
in children younger than 3 years, has decreased signiﬁcantly
the number of youngsters undergoing general anesthesia
for this diagnostic exploration [72]. Magnetic resonance
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anesthesia to ensure immobility in children who are unco-
operative. Forty children undergoing an MRI examination
received melatonin (10mg) 30min before the scheduled
MRI. A subgroup of these children was sleep deprived the
night before the exploration. The authors concluded that
melatonin, especially if associated with sleep deprivation,
improved the success rate of this diagnostic procedure [73].
However, in a stratiﬁed randomized double-blind study in
children, carried out on 98 patients treated with either
melatonin (3–6mg) or placebo 10min before they were
sedated with chloral hydrate or temazepam plus droperidol
for an MRI exam, melatonin did not contribute to sedation
[74].
4.MelatoninUses inEpilepsyand
FebrileSeizures
The fact that pinealectomy induced violent convulsions in
parathyroidectomiced rats as well as observations on the
epileptogenic eﬀects of melatonin antibodies intraventricu-
larly injected into rats [75, 76] was the ﬁrst data suggesting a
possible relationship between melatonin and epilepsy. In this
context, experimental studies demonstrate that suppression
of melatonin, by pinealectomy, increased the brain damage
after kainic acid-induced seizures in rats, thus suggesting
a neuroprotective role of melatonin [77] on neural tissue.
Melatonin was reduced in patients with epilepsy at baseline
compared with controls and increased threefold following
seizures [78]. Other authors have also reported that patients
with seizures of diverse origins show an alteration of the
melatonin rhythm [79, 80]. Recent studies, carried out in
children with refractory epilepsy or febrile seizures [81, 82],
revealed a lowered level of melatonin in these children in
comparison with those without seizures. Melatonin could
control convulsive crises by acting on both γ-aminobutyric
acid (GABA) and glutamate receptors [79, 80].
The ﬁrst trials on the possible usefulness of melatonin
in epilepsy were carried out on patients refractory to
conventionaltherapies.Althoughmelatoninalone,atasingle
evening dose of 5–10mg, has been reported to reduce the
frequency of epileptic attacks in children [83], most studies
have been focused on the use of melatonin associated with
otherconventionalantiepilepticdrugs(vigabatrin, valproate,
phenobarbital, etc.). One of the ﬁrst case reports was
concerned with a young girl diagnosed of severe myoclonic
epilepsy, with convulsive seizures since her ﬁrst month of
age; melatonin was added to the conventional treatment
(Phenobarbital) when the patient was in a precomatose
stage, at the age of 29 months. After one month of this
therapy and for a year thereafter, the child’s seizures were
under control [84]. In another study [85, 86]o nc h i l d r e n
with severe intractable seizures, a 3-month treatment with
oral melatonin (3mg/day, 30min before bedtime) associated
with a conventional antiepileptic drug achieved a signiﬁcant
clinical improvement in seizure activity during treatment,
particularly during the night.
The only negative results were reported in a trial on
a sample of six children treated with melatonin (5mg at
bedtime). Although melatonin had a positive eﬀect on the
patient’s sleep disorder, four of six children had elevated
seizureactivity aftertreatment[87].Thisstudyhad,however,
serious weaknesses. One major factor is the small number
and heterogeneity of patients: 6 cases with ages ranging from
9 months to 18 years; the comparison between neonatal,
infant, or juvenile response to the same doses of melatonin
seems inappropriate. Furthermore, the neurological lesions
of the six patients are also markedly diﬀerent. Moreover,
the hypothesis of the proconvulsant eﬀects of melatonin has
never been conﬁrmed in subsequent studies. Other authors
[88] also found that melatonin can be helpful for sleep
disturbance in young people with signiﬁcant neurological
impairment although did not ﬁnd a demonstrable inﬂuence
of the indoleamine on seizure control.
Since melatonin plays a protective role against the oxida-
tive stress and prevents neuronal damage associated with
epilepsy, several clinical trials were focused on the evaluation
of the changes in the oxidative status of the patients treated
with melatonin alone or associated with otheranticonvulsive
drugs. In relation to this, 31 children with epilepsy receiving
carbamazepine monotherapy [89] and 31 other children
treated with valproate [90, 91], who were seizure-free at
least for the last 6 months, were involved in a double-
blind, randomized, parallel-group, placebo-controlled trial.
The eﬀect of add-on melatonin (6–9mg/day for 14 days)
on the antioxidant enzymes glutathione peroxidase and
glutathione reductase demonstrated that melatonin is a
putative neuroprotector in conditions involving oxidative
stress such as that occurs in epilepsies.
Children with epilepsy have high rates of sleep problems
due to seizures or anxiety, frequently associated to mental
retardation. Twenty-ﬁve patients (16 males and 9 females;
mean 10.5 years) with these characteristics were randomized
tooralfast-release melatoninatbedtime(3mg/dayextended,
in case of ineﬃcacy, up to 9mg/day at 3mg/week steps)
or placebo. Patients treated with melatonin improved their
wake-sleep disorders although the seizure frequency was
poorlyinﬂuencedbythetreatment[92].Amorerecentstudy,
conducted on 23 children with intractable epilepsy treated
with oral melatonin before bedtime for 3 months, noticed
a signiﬁcant improvement of both sleep-related phenomena
and the severity of seizures in these patients [93].
Although the antiepileptogenic properties of ramelteon,
a selective melatoninreceptoragonistrecentlypatented,have
been described in a rat model of chronic epilepsy [94],
clinical trial on its eﬃciency for human treatment has not
been studied.
5.Melatonin UsesinAdolescentIdiopathic
Scoliosis(AIS)
The hypothesis involving a melatonin deﬁciency as the
source for AIS stems from the fact that experimental
pinealectomy in the chicken, rats, rabbits, Atlantic salmon,
and mice with genetic deﬁciency of melatonin forced into a
bipedal mode of locomotion results in scoliosis that closely
resembles AIS [95, 96].6 International Journal of Pediatrics
In humans, Sadat-Ali et al. [97] found serum melatonin
levels to be signiﬁcantly lower in AIS patients than in
healthy controls; these results support the hypothesis that
serum melatonin levels may contribute to the pathogenesis
of AIS. However, these ﬁndings were not corroborated by
other authors [98–102]. Studies based on the screening of
polymorphism in genes coding for melatonin receptors or
enzymes involved in melatonin synthesis in AIS patients and
controls have generated disparate results [103–106]. A third
category of studies, those looking for possible diﬀerences
in the expression of melatonin receptors in paravertebral
musclesontheconcaveandconvexsidesofthespinalcolumn
inAISpatients,didnotuncoverconclusiveresults[107,108].
A new and interesting approach to the question of the
possible role of melatonin in the etiology of AIS is to
consider that instead of changes in melatonin production
or expression of melatonin receptors, the problem may be
an anomalous response of the osteoblast to melatonin in
AIS patients [109]. In most cells, melatonin inhibits the
forskolin-stimulated adenylyl cyclase activity and decreases
cAMP. In contrast, osteoblasts from patients with AIS
showed a lack or a marked inhibition by melatonin of the
forskolin-stimulated adenylyl cyclase activity [109]. From
these ﬁndings, a preliminary molecular classiﬁcation of
AIS patients based on the cellular response to melatonin
(changes in cAMP) has been proposed [110]. Recently,
these authors [110, 111] have also developed the ﬁrst blood
test, based on the cellular reaction to melatonin, to detect
children without symptoms who are at risk of developing
scoliosis. A prospective analysis on the correlation of serum
melatonin levels (monitored yearly for 3–6 years) and curve
progression in 40 patients with moderate to severe AIS [112]
showed that, from 22 patients with melatonin levels similar
to healthy age-matched controls, 16 had stable scoliosis
whereas 6 had progressive scoliosis. The 16 patients with low
melatonin levels were treated with oral melatonin (3.0mg
1.5–2.0hr before the desired sleep time). Twelve of them
developed stable scoliosis, whereas four continued to have a
progressive course of the disease. This is the ﬁrst description
suggesting that melatonin supplementation may prevent the
progression of the scoliosis, especially in mild cases.
6.M elat on inU s esinN eon atalCar e
Since newborns and particularly those delivered preterm
have less protection against oxidation and are highly suscep-
tible to free radical-mediated oxidative damage, melatonin,
because of its antioxidant properties, could be useful to
reduce oxidative stress in neonates with sepsis, asphyxia,
respiratory distress, or surgical stress [113]. These possibil-
ities were exploited in diﬀerent clinical trials carried out in
the Neonatal Intensive Care Unit of the Institute of Medical
Pediatrics of the University of Mesina (Italy).
In one of these studies, 20 newborns with perinatal
asphyxia diagnosed within the ﬁrst 6 hours of life were
investigated along with 10 healthy infants. In a random
manner, 10 asphyxiated infants receivedmelatonin (80mg in
8 doses of 10mg, each separated by 2-hour intervals). Three
of the 10 asphyxiated children not given melatonin died
within 72hrafterbirth;noneofthe10asphyxiated newborns
given melatonin died. In the asphyxiated newborns given
melatonin, there were signiﬁcant reductions in malondialde-
hyde and nitrite/nitrate levels at both 12 and 24 hours, thus
indicating the antioxidant eﬀect of melatonin [114].
The utility of melatonin as an adjuvant treatment for
sepsis was evaluated in a similar randomized clinical trial
which included 20 septic newborns; ten of whom received
a total of 20mg of melatonin orally in two doses of 10mg
each, with a 1h interval, within the ﬁrst 12h after diagnosis.
Three of 10 septic children who were not treated with
melatonin (controls) died within 72 hours after diagnosis
of sepsis, whereas none of the 10 septic newborns given
melatonin died. Serum levels of lipid peroxidation products,
asmarkersofoxidativestress,insepticnewbornstreatedwith
melatonin were signiﬁcantly lower than in placebo-treated
infants [115].
A third randomized trial [116] recruited 74 newborns
with grade III or IV respiratory distress syndrome. Patients
received 10 doses of melatonin (10mg/kg each; 40 patients)
or placebo (the remaining 34 cases). Melatonin signiﬁcantly
decreased the severity of respiratory distress syndrome
compared to infants receiving placebo.
Finally, the usefulness of melatonin to reduce oxidative
stress related to surgical procedures was investigated in 40
newborns with diﬀerent pathologies subjected to surgical
treatment. Ten patients received a total of 10 doses of
melatonin (10mg/kg) at deﬁned intervals for 72 hours by
means of intravenous infusion. Ten surgical neonates did not
receive melatonin but were given an equalvolume of placebo
(1:50mixtureofethanol-physiologicsaline).Twenty healthy
neonates served as control for basal levels of cytokines and
nitrite/nitrate. Melatonin reduced postoperative values of
cytokines and nitric oxide synthesis in relation to placebo,
thus supporting its potent antioxidant properties which
resulted in improvement of clinical outcome [117].
7.Melatonin Usesinthe Feeding ofNewborns
It is well documented that melatonin exhibits a circadian
rhythm in body ﬂuids, and human milk is no exception.
Melatonin in the milk of lactating mothers exhibits a
marked daily rhythm, with high levels during the night and
undetectable levels during the day [118]. This melatonin
rhythm in milk could serve to communicate time of day
information to breast-fed infants; this information could
also contribute to the consolidation of sleep-wake rhythm
of infants until the maturation of their own circadian
system occurs. Considering this data, several issues must
be considered. First is the importance of nocturnal breast
feeding in darkness given that exposure to light causes the
suppression of melatonin in breast milk. Second, in milk
banks, it may be important to diﬀerentiate milk obtained
from donors during day versus that collected at night, in
order to feed newborns with the milk corresponding to the
appropriate periods. Third, for synthetic milk formulations,
the composition should diﬀer for night and day products, toInternational Journal of Pediatrics 7
achieve a chronobiologic eﬀect on the circadian rhythm in
newborns. Thus, it may be worthy to consider the addition
of melatonin, melatonin analogues, or melatonin precursors
to night milk formulas.
In regard to this, there is a growing international
interest in the development of milk and milk products
with a high melatonin contents (patents WO/2001/001784,
WO/2007/068361, and US 2008/0058405 A1). In a three-
week duration, double-blind trial on 30 infants aged 4–20
weeks with sleeping diﬃculties, children received “day milk,”
with low levels (1.5gr/100g protein) of tryptophan, the
aminoacid precursor of melatonin, or “night milk,” contain-
ing higher levels of tryptophan (3.4gr/100g protein) from
06:00 to 18:00 or from 18:00 to 06:00. When the children
received the day/night-dissociated milk in concordance with
their environment, they showed a signiﬁcant improvement
in the nocturnal sleep parameters that were analyzed (total
sleep, sleep eﬃciency, nocturnal awakenings, and sleep
latency)[119].The urinary metabolitesofserotonin onthese
childrensuggestthattheobservedimprovementsweredueto
an elevated use of serotonin to melatonin synthesis [120].
8.ConcludingRemarks
Melatonin, based on its properties as chronobiotic (sleep
modulation), antioxidant, or analgesic, all of which have
been conﬁrmed in numerous experimental studies, oﬀers
perspectives of beneﬁcial eﬀects in a variety of pediatric
therapies. These beneﬁcial eﬀects have been demonstrated
for sleep disorders of diﬀerent etiologies, not only primary
butalso associated with mental, neurologic,orothermedical
disorders. Regarding this issue, it is important to point out
that sleep disordersof children with orwithout developmen-
tal disabilities are basically of circadian origin and depend
on the extent and severity of brain dysfunction rather than
on the cause of the condition which initiated neurological
problems. Therefore, the dose of melatonin applicable to
each patient must vary according to multiple factors such
as the child’s medical problems, the severity and type of
sleep problems, or the associated neurological pathology.
Interesting results have also been reported in the treatment
of epilepsy, which show that melatonin reduces not only the
convulsive seizures but prevents neuronal damage associated
with seizures and improves sleep quality in these patients.
The hypothesis of the possible role of a melatonin deﬁcit
in the etiology of adolescent idiopathic scoliosis encouraged
its use and showed that it delayed the progression of the
spinal scoliosis in children with low melatonin levels. In
neonatal therapy, the antioxidant properties of melatonin
have been the basis for its administration to newborns to
reduceoxidative stress caused by sepsis, asphyxia, respiratory
distress, or surgical stress. The feeding of infants with either
breast or formula milk with diﬀerent concentration of mela-
tonin for the night and at day meals contributed to a better
consolidation of the sleep/wake rhythm of the children. It
is noteworthy that signiﬁcant side eﬀects of melatonin in
children have not been reported [5]. In conclusion, there is
certainly clinical evidence for the usefulness of melatonin in
the treatment of some pediatric pathologies. However, the
number of controlled clinical trials is still small, and speciﬁc
studies to resolve problems of dosage, formulations (slow or
fast release), and length of treatment are desirable.
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